HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Overexpression of vascular endothelial growth factor-B in mouse heart alters cardiac lipid metabolism and induces myocardial hypertrophy.

Abstract
Vascular endothelial growth factor (VEGF)-B is poorly angiogenic but prominently expressed in metabolically highly active tissues, including the heart. We produced mice expressing a cardiac-specific VEGF-B transgene via the alpha-myosin heavy chain promoter. Surprisingly, the hearts of the VEGF-B transgenic mice showed concentric cardiac hypertrophy without significant changes in heart function. The cardiac hypertrophy was attributable to an increased size of the cardiomyocytes. Blood capillary size was increased, whereas the number of blood vessels per cell nucleus remained unchanged. Despite the cardiac hypertrophy, the transgenic mice had lower heart rate and blood pressure than their littermates, and they responded similarly to angiotensin II-induced hypertension, confirming that the hypertrophy does not compromise heart function. Interestingly, the isolated transgenic hearts had less cardiomyocyte damage after ischemia. Significantly increased ceramide and decreased triglyceride levels were found in the transgenic hearts. This was associated with structural changes and eventual lysis of mitochondria, resulting in accumulation of intracellular vacuoles in cardiomyocytes and increased death of the transgenic mice, apparently because of mitochondrial lipotoxicity in the heart. These results suggest that VEGF-B regulates lipid metabolism, an unexpected function for an angiogenic growth factor.
AuthorsTerhi Karpanen, Maija Bry, Hanna M Ollila, Tuulikki Seppänen-Laakso, Erkki Liimatta, Hanna Leskinen, Riikka Kivelä, Teemu Helkamaa, Mari Merentie, Michael Jeltsch, Karri Paavonen, Leif C Andersson, Eero Mervaala, Ilmo E Hassinen, Seppo Ylä-Herttuala, Matej Oresic, Kari Alitalo
JournalCirculation research (Circ Res) Vol. 103 Issue 9 Pg. 1018-26 (Oct 24 2008) ISSN: 1524-4571 [Electronic] United States
PMID18757827 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
Chemical References
  • Ceramides
  • Triglycerides
  • VEGFB protein, human
  • Vascular Endothelial Growth Factor B
  • Angiotensin II
  • Ventricular Myosins
  • Myosin Heavy Chains
Topics
  • Angiotensin II
  • Animals
  • Blood Pressure
  • Capillaries (metabolism, pathology)
  • Cardiomegaly (metabolism, pathology, physiopathology)
  • Cardiomyopathies (metabolism, pathology, physiopathology)
  • Cell Size
  • Ceramides (metabolism)
  • Coronary Vessels (metabolism, pathology)
  • Disease Models, Animal
  • Heart Rate
  • Humans
  • Hypertension (chemically induced, genetics, physiopathology)
  • Lipid Metabolism
  • Mice
  • Mice, Transgenic
  • Mitochondria, Heart (metabolism, pathology)
  • Myocardial Ischemia (metabolism, physiopathology)
  • Myocardium (metabolism, pathology)
  • Myocytes, Cardiac (metabolism)
  • Myosin Heavy Chains (genetics)
  • Neovascularization, Physiologic
  • Oxidation-Reduction
  • Promoter Regions, Genetic
  • Skin (blood supply, metabolism)
  • Time Factors
  • Triglycerides (metabolism)
  • Up-Regulation
  • Vascular Endothelial Growth Factor B (genetics, metabolism)
  • Ventricular Function, Left
  • Ventricular Myosins (genetics)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: